This post was originally published on this site
© Reuters.Investing.com — Here is a rundown of regulatory news releases from the London Stock Exchange on Friday, 15th November. Please refresh for updates
- Gambling group 888 Holdings (LON:) said it’s sticking by non-executive chairman Brian Mattingley despite a strong vote against him by shareholders at its annual meeting in May.
- “The Board’s decision to retain Mr. Mattingley as its Non-Executive Chairman reflects the significant value he brings to the Board, including in particular his wealth of gambling industry and public company experience, deep knowledge of the business and industry contacts,” the company said, adding that “Mr. Mattingley’s continued tenure as Non-Executive Chairman benefits all shareholders.”
-
- 888 has badly underperformed rivals GVC (LON:) and Flutter Entertainment (LON:) over the last 18 months, in which its share price has fallen some 40%.
- Rio Tinto (LON:) said it will pay $221 million to support a clean-up project after the closure of a mine in Australia’s Northern Territory.
- The rehabilitation of the Ranger Project Area is expected to cost $324 million in total.
- Under the terms of its mining approvals, the operating company ERA, in which Rio has a 68.4% stake, is required to end mining and processing activities at Ranger by January 2021 and complete final rehabilitation by January 2026.
- Telecom network operator Talk Talk (LON:) swung to a pretax profit of 1 million pounds ($1.29 million) in the first half of its 2020 fiscal year, thanks to a surge in new fiber customers.
- Like-for-like EBITDA rose 14% on the year, as it added a net 292,000 customers for its fiber network, up from 192,000 additions a year earlier. It did particularly well in the second quarter, accounting for 33% of all Openreach Fiber-to-the-Cabinet lines.
- Revenue fell 3.6% due to discontinued businesses.
- The company kept its EBITDA outlook for the full year unchanged.
- Pharma group AstraZeneca (LON:) said the EU had approved its Qtrilmet drug for treating adults with type-2 diabetes (T2D).
Qtrilmet was approved in the US in May 2019 under the name Qternmet XR
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
